Judicialização por Medicamentos do Componente Especializado da Assistência Farmacêutica no Estado de Minas Gerais.

Abstract

In recent years, the legal route has become an increasingly used strategy to guarantee access to different health technologies in Brazil, including medicines subsidized by the Unified Health System (SUS). This project aimed to describe the lawsuits filed against the state of Minas Gerais (EMG) that have as their object of action the drugs of the “Specialized of Component Pharmaceutical Assistance” (CEAF), normally acquired and financed by the Ministry of Health (CEAF-group 1A; CEAF-1A). A documentary, descriptive and quantitative study was conducted withthe lawsuits registered at the Health Judicialization Center (NJS) of the State Health Department. lawsuits in the NJS, in which there was an obligation to comply with one or more CEAF-1A drugs, until December 2019. The descriptive analysis of the categorical variables was presented as percentages and, as support for the data analysis, the software was used SPSS®. The study evaluated 11,936 lawsuits filed against the EMG, there was a greater number of new lawsuits in 2014, 2015 and 2016 and a downward trend from 2017 onwards. Litigations for the 11,513 beneficiaries were predominantly individual (99.68%) and the filing of more than one lawsuit by the same beneficiary was identified. When relating the total number of beneficiaries with the size of the population, it was observed that the Regional Health Unit (URS) of Divinópolis has a higher index (IMJS=8.34), however, in relation to the absolute number, the URS of Belo Horizonte concentrated the majority of beneficiaries (26.48%). From the list of 130 medicines in the CEAF-1A, claims were identified for 118 items, in 20.34% of the medicines their unavailability in the SUS was identified. Ten medicines were responsible for 80% of the expenses and it was demonstrated that the state resource destined to the fulfillment of the legal demands was 90% superior to the resource destined by the Ministry of Health for the acquisition of the same medicines in identical quantities. It was concluded that there is a need to create mechanisms that favor the de-judicialization of the EMG, with a view to a more rational management of resources destined to the pharmaceutical assistance policy.